NeuroSense (NRSN) CTO awarded 200,000 restricted shares vesting over two years

NeuroSense Therapeutics (NRSN) announced a redesigned development strategy for PrimeC in ALS, aiming to accelerate regulatory approval and reduce costs. The strategy includes AI-enabled formulation analysis, a comparative study against edaravone, and an optimized Phase 3 trial design. The company has received FDA clearance and is targeting a Canadian regulatory submission by December 2026. PrimeC is an investigational oral therapy combining ciprofloxacin and celecoxib.

NeuroSense Therapeutics (NASDAQ: NRSN) said its Phase 2b PARADIGM trial of PrimeC in ALS met the primary endpoint: at Day 180, TDP-43 fell vs placebo (p=0.0421), with differences sustained at Day 540 (p<0.001). The company also reported slower ALSFRS-R decline and a median survival benefit (HR 0.35, p=0.004), plus no new safety signals, and said FDA clearance was obtained for Phase 3.

Volkswagen appointed Marco Schubert as North America chief, replacing Kjell Gruner. Schubert will join the Extended Executive Committee on Oct. 1. The move follows declining U.S. sales, down 13.6% in 2025 and 7.4% in H1 2026. Schubert has 25+ years of experience at Volkswagen Group, including roles at Audi, Skoda, and Porsche.

Merck (MRK) stock has surged 84% in the past year, outperforming peers, despite its revenue growth and profitability lagging. The market is betting on its pipeline, valued at over $70B, to offset Keytruda's patent expiration. LIPFENDRA's launch and sales will be key indicators of Merck's ability to deliver on its future prospects.

Walmart and Inspire Brands (Dunkin's parent) announced a deal to offer Dunkin' items for delivery alongside Walmart orders. The service will initially launch at 150 Dunkin' locations inside Walmart stores, expanding to most of Dunkin's 10,000 U.S. locations. Walmart's delivery network, which grew 48% last quarter, will facilitate the service. According to Walmart, 90% of the U.S. population lives within 10 miles of a Walmart store.

Shore Capital reiterated a 'sell' rating on HSBC (HSBA, HSBC), citing a high valuation and a 1,335p target price, implying 13% downside. HSBC management reported strong trading across most businesses, healthy wealth client acquisition, and growing fee income. However, Shore Capital warned of potential future profitability challenges and an optimal but unsustainable interest rate environment.